Abstract: 35 patients with the “complet form“ of Behcet’s disease, according to the criteria of Behcet’s Disease Research Committee of Japan were selected for study. The choice of complet forms make possible to have a more homogenous group of patients to evaluate the effect of levamisole on the major symptoms of the disease. The patients were treated with levamisole at least for 3 to 6 months, they had no cytotoxic ...
TREATMNT OF OPHTHALMOLOGIC MANIFESTATIONS OF BEHCET'S DISEASE. ANALYSIS OF 6 DIFFERENT TREATMENT MODALTLES
Abstract: INTROUCTION: Ophthalmologic manifestations are the major cause of morbidity in Behcet's Disease. If not treated, they usually progress toward sever loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents. MATERIALS & METHOD: In an open, non randomized, control study, Pulse Cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), weakly methotrexate (MTX), chlorambucil (CHL), oral cyclophosphamide (OCP), and cyclosporine A (CYA) were used in a standard protocol for 778 ...
Histocompatibility antigens (HLA) in rheumatic diseases in Iran
Abstract: One hundred and sixty-six patients with different forms of rheumatic diseases were tissue typed for 26 antigens of the A and B locus of the HLA system, using a modified KN cytotoxicity test. Among 25 patients with confirmed ankylosing spondylitis, 23 had HLA B27 (92 per cent), compared to 2.5 per cent in the normal controls. This confirms the strong association of HLA B27 with ankylosing spondylitis. Eight patients had ...